Disal® Injection — veterinary medication

Overview

Source: Animal Drugs @ FDA

Proprietary name

Disal® Injection

Active ingredient

Furosemide

Application type

NADA

Sponsor

Boehringer lngelheim Animal Health USA, Inc.

Applications on record

1

First published

November 13, 2017

Adverse event reports

Source: openFDA VeDDRA

2,034

Reports mentioning this ingredient

January 20, 1987 – March 24, 2026

941

Classified serious

per reporter assessment

195

Lack of expected efficacy

resistance signal

57

Human operator exposure

needle-stick or splash

Not a risk measure. Veterinary adverse event reports are influenced by how many animals are treated, reporting practice and product age. Reports do not establish that the product caused the event, and a single report can cover an entire herd or flock. Attribution here is by active ingredient because the source dataset redacts brand names.

Attributed by active ingredient “FUROSEMIDE”. Green Book ingredient names and VeDDRA ingredient names do not always agree exactly, so attribution is approximate and labelled as such.

Reported reactions

Source: openFDA VeDDRA

Clinical signs coded in the VICH VeDDRA four-level hierarchy, most frequent first.

Reaction terms reported for this ingredient, by report count.
Reaction (VeDDRA term)	Reports	Relative frequency
Color, Abnormal	214
Solution, Abnormal	137
Tablets, Abnormal	73
Accidental exposure	35
Death	28
Product Defect, General	19
Lack of efficacy - NOS	18
Depression	18
Uncoded sign	17
Polyuria	14
Vials, Damaged	14
Death by euthanasia	13
Contamination NOS	12
Elevated blood urea nitrogen (BUN)	11
Product label issues	11
Elevated creatinine	10
Vomiting	9
No sign	9
Anorexia	8
Tachycardia	7

Species affected

Source: openFDA VeDDRA

Dog 1,325 Cat 260 Horse 22 Human 13 Cattle 5 Other Birds 2 Pig 2 Ferret 1

Regulatory context

New Animal Drug Application (NADA). A pioneer approval evaluated for target animal safety, therapeutic effectiveness, manufacturing controls and — for food-producing species — human food safety including residue depletion.

Extra-label use in food-producing animals is governed by the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) and 21 CFR Part 530. It requires a valid veterinarian-client-patient relationship and is prohibited outright for certain drug classes. Withdrawal times are determined by FARAD, not by this index.

Sources for this page

Animal Drugs @ FDA	FDA CVM	Applications, sponsor, status, withdrawal
Animal & Veterinary Events	FDA CVM	VeDDRA adverse event aggregates by active ingredient